{"created":"2014-08-13T19:55:46+00:00","modified":"2015-05-14T20:26:28+00:00","valid":{"from":"2014-02-20T17:05:37+00:00","to":"3014-02-20T17:05:37+00:00"},"hreflang":"en","title":"When you're the 'new pharma' in town","contentencoded":"<div class=\"barn-cleaned\"><p>When you're playing in the big leagues of \"big pharma,\" getting investors to believe in your product is a tough game.</p>\n<p>Barry Werth, author of \"<a href=\"http://www.amazon.com/The-Antidote-Inside-World-Pharma-ebook/dp/B00DPM7ZW6/ref=dp_kinw_strp_1\" target=\"_blank\">The Antidote</a>\" examines how founder Joshua Boger left <span>Merck, the&nbsp;</span>pharmaceutical Goliath, in 1989 to create Vertex -- with a plan to change the infrastructure of how medicine is made and distributed.</p>\n<p>\"He wrote down three things: one was to make better drugs faster, second was become Merck but better, and the third was build the 21st century bio-pharmaceutical company,\" Werth says.</p>\n<p>Getting to a scientific break-through or developing a wonder drug is a game of high-stakes investment. The costs are huge, timelines are extensive, and the risk of failure is great.</p>\n<p>According to Werth, it's a gamble that only Wall Street can handle.</p>\n<p>\"There's no place to raise that kind of money but Wall Street...1 in 300 ideas that you have gets to market and the other 299 crash and burn. In clinical trials 1 in 30, or 3 percent, make it to the finish line,\" he says.</p>\n<p>The pressures of Vertex to continue its funding ultimately paid off.</p>\n<p>Werth cites that Vertex's hepatitis C drug took 18 years before it hit the market. The drug then made $1.3 billion in its first year.</p></div>","teaser":"How a small pharmaceutical company triumphed over the pressures of Wall Street and 'big pharma.'","itags":["PMP:Marketplace_PMP","Marketplace","021456fbb56095aebec117ddc0adaa54","Marketplace for Thursday, February 20, 2014"],"published":"2014-02-20T17:05:37+00:00","guid":"021456fb-b560-495a-8bec-17ddc0adaa54","tags":["Health Care","APM","pharmaceuticals"],"description":"How a small pharmaceutical company triumphed over the pressures of Wall Street and 'big pharma.'","byline":"Kai Ryssdal","contenttemplated":"[{\"type\":\"text/html\",\"content\":\"<p>When you&apos;re playing in the big leagues of &quot;big pharma,&quot; getting investors to believe in your product is a tough game.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>Barry Werth, author of &quot;<a href=\\\"http://www.amazon.com/The-Antidote-Inside-World-Pharma-ebook/dp/B00DPM7ZW6/ref=dp_kinw_strp_1\\\" target=\\\"_blank\\\">The Antidote</a>&quot; examines how founder Joshua Boger left <span>Merck, theÂ </span>pharmaceutical Goliath, in 1989 to create Vertex -- with a plan to change the infrastructure of how medicine is made and distributed.</p>\"},{\"content\":\"<p>&quot;He wrote down three things: one was to make better drugs faster, second was become Merck but better, and the third was build the 21st century bio-pharmaceutical company,&quot; Werth says.</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>Getting to a scientific break-through or developing a wonder drug is a game of high-stakes investment. The costs are huge, timelines are extensive, and the risk of failure is great.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>According to Werth, it&apos;s a gamble that only Wall Street can handle.</p>\"},{\"content\":\"<p>&quot;There&apos;s no place to raise that kind of money but Wall Street...1 in 300 ideas that you have gets to market and the other 299 crash and burn. In clinical trials 1 in 30, or 3 percent, make it to the finish line,&quot; he says.</p>\",\"type\":\"text/html\"},{\"content\":\"<p>The pressures of Vertex to continue its funding ultimately paid off.</p>\",\"type\":\"text/html\"},{\"content\":\"<p>Werth cites that Vertex&apos;s hepatitis C drug took 18 years before it hit the market. The drug then made $1.3 billion in its first year.</p>\",\"type\":\"text/html\"}]","audio":[{"href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/175052331.jpg?itok=_Uy8VOQD","meta":{"height":"340","crop":"primary","width":"610"},"type":"image/jpeg"},{"format":"MP3","meta":{"duration_hms":"00:05:11","duration":311,"api":{"href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2014/02/20/marketplace_segment22_20140220","type":"application/json"}},"href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2014/02/20/marketplace_segment22_20140220_64.mp3","type":"audio/mpeg"}]}